Parallel Advisors’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCRX
Parallel Advisors's PCRX Position: Q3 2026 in Review
Parallel Advisors held its Pacira BioSciences (PCRX) position steady in Q3 2026 at 178 shares worth $4.46K. The position accounts for ﹤0.01% of the portfolio, ranked #3410.
Parallel Advisors first reported a position in PCRX in Q2 2022 and has held it in 16 quarters since. The position peaked at $9.45K in Q4 2023. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.
- Parallel Advisors held 178 shares of Pacira BioSciences worth $4.46K as of Q3 2026.
- Parallel Advisors left its Pacira BioSciences share count unchanged in Q3 2026.
- Pacira BioSciences made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3410 holding.
- Parallel Advisors first reported a position in Pacira BioSciences in Q2 2022 and has held it in 16 quarters since.
- Parallel Advisors's Pacira BioSciences position peaked at $9.45K in Q4 2023.
- 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.
Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.